Signal Transduction Inhibitors in the Treatment of Breast Cancer

Title: Signal Transduction Inhibitors in the Treatment of Breast Cancer

Volume: 3 Issue: 3

Author(s): Rita Nahta, Gabriel N. Hortobagyi and Francisco J. Esteva

Affiliation:

Keywords: breast neoplasm, biological therapy, egfr, her-2, monoclonal antibodies, tyrosine kinase inhibitors, farnesyl transferase inhibitors

Abstract: Signal transduction pathways are frequently altered in human breast cancer and are the targets of several novel therapies currently in clinical trials. Therapeutic strategies include extracellular blockade of tyrosine kinase receptors with the monoclonal antibodies C225 and trastuzumab. Competitive inhibitors of adenosine triphosphate binding sites on tyrosine and serine / threonine kinases are also being evaluated in phase I / II trials, these include ZD1839, OSI-774 and CI- 1033. Flavopiridol and UCN-01 are nonspecific cell cycle kinase antagonists with preliminary evidence of breast cancer cell growth inhibition. Several inhibitors of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling are also in various stages of preclinical or clinical development. Additionally, inhibitors of farnesyl transferase have demonstrated activity in breast cancer cells irrespective of ras status. Current evidence suggests that targeting of signaling molecules is a promising new approach to treatment of breast cancer.

Cite this article as:

Nahta Rita, Hortobagyi N. Gabriel and Esteva J. Francisco, Signal Transduction Inhibitors in the Treatment of Breast Cancer, Current Medicinal Chemistry - Anti-Cancer Agents 2003; 3 (3) . https://dx.doi.org/10.2174/1568011033482468